Introduction
CD40-CD154 (CD40-ligand) interactions are critical for immune recognition.
1,2 CD154 is transiently expressed on CD4 + T cells following T cell receptor (TCR) engagement by antigen-presenting cells through major histocompatibility complex (MHC) class II molecules. [3] [4] [5] [6] This, in turn, can cause activation of CD40-expressing antigen presenting cells (APCs), including B cells, dendritic cells, monocytes, and macrophages. 7, 8 Such CD40-activated cells can set off a cascade of immune-activating events that lead to a specific and effective immune response against foreign antigens, such as viruses or tumors.
9, 10 The importance of CD40-CD154 interactions is underscored by the finding that individuals who have inherited defects in the ligand for CD40 have a profound immune deficiency. 11, 12 Such patients have an immune deficiency syndrome associated with impaired germinal center formation, defective isotype switching, and marked susceptibility to various bacterial and viral pathogens.
In light of the role that this receptor-ligand pair plays in immune regulation, the potential for using CD154 for immunotherapy is under active investigation. For example, chronic lymphocytic leukemia (CLL) B cells modified to express CD154 using a replication defective adenovirus vector can enhance CLL antigen presentation and induce autologous T cell cytotoxicity towards nonmodified CLL B cells. 13 Moreover, a phase I clinical study using Ad-CD154 modified CLL B cells has shown promising therapeutic results.
14 Similarly, other groups have shown that modification of various tumor types to express CD154 can induce effective anti-tumor immune responses in animal tumor models. [15] [16] [17] These encouraging results stimulated us to examine the feasibility of Ad-CD154 immunotherapy for other B cell malignancies. B cell lymphoma appears to be an excellent candidate disease for this approach because, similar to CLL, lymphoma B cells express CD40 and can be induced to express multiple immune co-stimulatory molecules upon CD40 ligation. 18, 19 Moreover, since lymphoma cells express clonally restricted immunoglobulins and generally harbor cytogenetic abnormalities, these cells should express somatically generated antigens that potentially could be targeted by the host immune system. 20 As such, we examined whether lymphoma B cells could be infected with recombinant adenovirus vectors. Furthermore, we studied the phenotype and immune function of such cells following infection with adenovirus encoding CD154.
Materials and methods

Patient samples
After obtaining informed consent, lymph node biopsies were performed on patients with B cell follicle center lymphoma and prepared into single cell suspensions, as described. 21 The cells then were subjected to density-gradient centrifugation over cushions of Ficoll-Paque PLUS (Amersham Pharmacia Biotech, Uppsala, Sweden) to isolate mononuclear cells, as per the manufacturer's instructions. The cells were suspended in fetal calf serum containing 10% dimethylsulfoxide (Sigma, St Louis, MO, USA) for storage in liquid nitrogen until use. Blood mononuclear cells were similarly prepared from either normal donors or follicle center lymphoma patients as indicated. Cell cultures were maintained in serum free AIM-V media (Gibco-BRL, Grand Island, NY, USA).
Adenovirus vector constructs
Replication-incompetent adenovirus vectors encoding murine CD154 (Ad-CD154), human CD154 (Ad-hCD154), or ␤-galactosidase (Ad-LacZ) cDNA were made as described. 13, 22 Each cDNA was flanked by the cytomegalovirus (CMV) promoter/enhancer on the 5Ј end and the bovine growth hormone polyadenylation signal sequence on the 3Ј end, allowing for high-level expression of the transgene mRNA in eukaryotic cells without 3Ј non-translated regulatory sequences. Purified, high-titer (eg 0.8-2 × 10 10 p.f.u./ml), recombinant adenovirus was produced by Molecular Medi-cine, LLC (San Diego, CA, USA; www.molecularmed.com) by anion-exchange chromatography, as described. [23] [24] [25] Adenovirus purity and titers were determined by high performance liquid chromatography (Figure 1 ) and by a plaque forming assay using 293 cells, as described. 26 
Flow cytometry
Cells were washed and suspended in staining buffer, composed of phosphate buffered saline (PBS, pH = 7.4) containing 3% fetal calf serum, 0.05% sodium azide, and 10 g/ml propidium iodide. Cells then were incubated with saturating amounts of fluorochrome-conjugated monoclonal antibody (mAb) for 30 min at 4°C. Stained cells were washed twice with staining buffer and analyzed using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, CA, USA). Dead cells and debris were excluded from the analysis by light scatter and by gating out cells that failed to exclude propidium iodide. We determined the percentages of cells that expressed the transgene product and the mean fluorescence intensity ratio (MFIR) of transgene-expressing cells to assess the relative expression levels of the transgene. The MFIR is calculated by dividing the mean fluorescence intensity (MFI) of cells that were stained with the fluorochrome-conjugated antigen-specific mAb by the MFI of cells that were stained with a control fluorochrome-conjugated mAb of the same isotype, but of irrelevant specificity. All antibodies were obtained from Pharmingen, Inc. (La Jolla, CA, USA). These included fluorescein-conjugated mAb specific for CD3, CD27, CD70, and CD80, and PE-conjugated mAbs specific for mouse CD154, human CD154, CD86, CD95, and CD71. In addition, we used CyChrome-conjugated mAb specific for HLA-DR and APCconjugated mAb specific for CD19.
Mixed lymphocyte reactions
Two days after the initial infection with adenovirus, the infected lymphoma stimulator cells were treated with 100 ng/ml mitomycin C for 1 h at 37°C to block proliferation. These cells then were washed three times to remove the mitomycin C. 10 5 mitomycin C-treated cells were then placed in each well of a 96-well U-bottom plate. Subsequently, 10 5 purified blood T cells from allogeneic normal donors or 10 5 autologous blood T cells were added to each well. In each case, the CD3 + T cells were isolated to Ͼ93% purity using the T Cell Negative Isolation Kit from Dynal, Inc (Lake Success, NY, USA), by which CD19, CD14, CD16, CD56, and HLA-DRpositive cells were depleted. For autologous MLR reactions, we added recombinant human interleukin-2 (IL-2; Biosource International, Cambridge, MA, USA) to each well to a final concentration of 25 ng/ml. For some samples, blocking-mAb specific for MHC-class I (clone W6/32) was added at 3 g/ml final concentration. Following 2 days' incubation, aliquots of the media were collected to measure IFN-␥ production by enzyme-linked immunosorbent assay (ELISA) using two IFN-␥-specific mAbs (Pharmingen) and the manufacturer's protocol. To assess cell proliferation, we added 3 H-thymidine to a final concentration of 0.5 Ci/well 5 days after the initiation of the MLR and then harvested the cells 12 to 16 h later to measure incorporated 3 H-thymidine using a cell harvester (Tomtec, Hamden, CT, USA) and a beta-scintillation counter (Wallac, Turku, Finland).
Results
Adenovirus infection of lymphoma cells
We initially determined if replication-incompetent adenovirus encoding either murine CD154 (Ad-CD154) or human CD154 (Ad-hCD154) could infect lymphoma B cells and result in surface expression of CD154. Each vector was prepared to hightiter and purity, as assessed via anion-exchange chromatography ( Figure 1 ). Following infection with Ad-CD154 or AdhCD154 at increasing MOI ratios, HeLa cells expressed surface mouse or human CD154, respectively ( Figure 2 ). Moreover, the levels of surface CD154 expression on HeLa cells were similar for either vector at the same relative MOI ratio ( Figure 2 ). Likewise, infection of lymphoma cells with Ad-CD154 also resulted in high expression levels of murine CD154 provided MOI ratios were у100 (Figure 2 ). However, infection of lymphoma cells with Ad-hCD154 did not result in significant expression of human CD154, even at MOI ratios of 1000 (Figure 2) .
Infection with Ad-CD154 at MOI ratios ranging from 100 to 1000 resulted in transgene expression by 20 ± 15% to 85 ± 18% of the CD19 + gated B cells (n = 7) (Figure 3a) . Moreover, inspection of the cell subsets infected with Ad-CD154 revealed that murine CD154 was expressed predominantly on CD19-positive cells (Figure 3b ). In contrast, relatively few CD19-negative cells, comprised mostly of CD3 + T cells, expressed CD154 following infection with Ad-CD154, even at high MOI ratios (Figure 3b ). Time course analysis also showed that CD154 transgene expression reached maximum levels approximately 2 days after infection and lasted for at least 7 days after infection (Figure 4 ).
Ad-CD154 induced B cell phenotypic changes
We examined whether infection with Ad-CD154 or AdhCD154 resulted in phenotypic changes in infected lymphoma B cells. In contrast to non-infected, Ad-LacZ infected, or Ad-hCD154 infected lymphoma B cells, only Ad-CD154 infected lymphoma B cells were induced to express immune accessory molecules, such as CD80, CD86, CD54, CD70, and CD95 ( Figure 5 ). In addition, Ad-CD154 infected lymphoma cells demonstrated reduced expression of CD27, as previously noted for CD40 stimulated normal and leukemia B cells. 8 We also investigated whether infection with Ad-CD154 affected lymphoma cell proliferation or survival in vitro. Equal numbers of Ad-CD154 or non-infected lymphoma B cells were cultured in AIM-V medium and assessed for viability and cell number over time. There were no significant differences detected between the numbers of Ad-CD154-infected vs noninfected lymphoma cells over time (Figure 6a) . Moreover, the viability of adenovirus-infected cells was not significantly different from that of non-infected cells (Figure 6b) . Furthermore, we found that ratios of B cells to T cells remained constant over time after infection, indicating that infection with Ad-CD154 did not reduce the relative numbers of T cells within the mononuclear lymph node cell population (data not shown).
Allogeneic mixed lymphocyte reactions
We examined whether Ad-CD154-infected lymphoma cells could stimulate allogeneic T cells in a mixed lymphocyte Leukemia reaction (MLR). Normal donor T cells were purified to Ͼ93% purity by depleting CD19, CD14, CD56, CD16, and HLA-DRpositive cells from isolated blood mononuclear cells of normal donors. Upon co-culture with mitomycin-C-treated Ad-CD154-infected lymphoma cells, the allogeneic T cells were induced to undergo proliferation at rates significantly greater than that observed with non-infected lymphoma cells or lymphoma cells infected with Ad-LacZ or Ad-hCD154 (Figure 7a) . Moreover, Ad-CD154-modified lymphoma cells induced these cells to produce significantly greater amounts of IFN-␥ than did lymphoma cells infected with any other adenovirus vector (Figure 7b ).
Autologous T cell responses
Similarly, Ad-CD154-modified lymphoma B cells were tested for their ability to stimulate autologous T cells. Each MLR was performed in serum-free culture medium to minimize the potential for presenting foreign serum antigens. Autologous CD3 + blood T cells incorporated significantly greater amounts of 3 H-thymidine upon co-culture with autologous Ad-CD154-infected lymphoma cells than they did when co-cultured with non-infected cells or lymphoma cells infected with Ad-LacZ (Figure 8a ). Furthermore, this response was significantly inhibited by an anti-HLA mAb, W6/32, consistent with the response being restricted by MHC class I antigens.
We also examined for phenotypic changes in lymph node T cells from these patients with follicle center lymphoma following ex vivo adenovirus infection. We found that nodal T cells were induced to express MHC class II antigen (HLA-DR) and transferrin receptor (CD71) following infection of the lymphoma B cells with Ad-CD154 (Figure 8b ). Two days after the initial infection, an average of 36% (±10% s. 
Discussion
This is the first report of successful gene transfer to human primary follicle center lymphoma B cells. We prepared hightiter adenovirus vectors of high purity for infection of mononuclear cells isolated from the lymph nodes of patients with follicular B cell lymphoma. Nearly all CD19-positive lymphoma B cells within lymph node cell preparations could be made to express a transgene within 24 h after infection. This required that we infect the cells at MOI ratios that were approximately 10-fold higher than that required for effective gene transfer into HeLa cells. Nevertheless, we found that the CD19-positive lymphoma cells were among the most sensitive cells to adenovirus infection within such lymph node preparations. On the other hand, the T cells within these preparations were relatively resistant to infection (Figure 3) . The relative sensitivity of lymphoma B cells to infection with adenovirus vectors may obviate having to isolate lymphoma B cells from other cell types prior to infection to achieve selective gene transfer into neoplastic B cells.
Despite having similar titer and purity, the adenovirus vector encoding human CD154 failed to effect expression of human CD154 on lymphoma B cells. Since both human and murine CD154 were driven by the heterologous CMV promoter/enhancer, had similar Kozak sequences, and lacked 3Ј non-translated sequences that could mitigate transcript stability, the differential expression of these transgenes is unlikely due to differences in transcriptional regulation or translation initiation. In addition, infection of HeLa cells with either Ad-hCD154 or Ad-CD154 resulted in similar, high-level expression of the CD154 protein on the plasma membrane at the same MOI ratio. Thus, the failure of hCD154 cannot be due to differences between adenovirus preparations or in the sensitivity of our detection methods. Still, lymphoma B cells failed to express the human CD154 even at MOI ratios that were sufficient to allow for high-level expression of the murine homologue. These results suggest that a post-transcriptional block precludes expression of human CD154 on the surface of the lymphoma B cells. The inability to effect expression of the human CD154 on lymphoma B cells contrasts with other reports indicating that normal or neoplastic B cells can express cell-surface CD154. [27] [28] [29] [30] Conceivably, the lymphoma B cells examined in this study represented cells at different states of B cell activation or differentiation, in which they were precluded from expressing this surface molecule. Alternatively, there may be heterogeneity among neoplastic B cells in their ability to express cell-surface CD154. Consistent with this, we find that neoplastic plasma cells from patients with multiple myeloma can be made to express human CD154 following infection with Ad-hCD154 infection (data not shown). 
Figure 6
Cell count and viability time course following Ad-CD154 infection. 5 × 10 6 lymphoma cells were either non-infected (squares) or infected with adenovirus at an MOI of 300 (circles). Aliquots were sampled from 1 to 7 days and both cell concentration (a) and viability (b) were determined. Error bars represent standard deviations (n = 4).
Human CD154 may exist as a soluble molecule 31, 32 that can bind cells that bear its cognate receptor, namely CD40. Consistent with this, we noted that CD40-bearing leukemia B cells could be stained with mAbs specific for human CD154 after a brief incubation at 4°C with non-purified lysates of AdhCD154-infected 293 cells that contained soluble CD154 (data not shown). Conceivably, the surface expression of human CD154 on B cells noted by others similarly may have been secondary to the cytophilic-binding of soluble CD154 to CD40. However, because soluble human CD154 protein is not present in the highly purified preparations of AdhCD154 used in these studies, we were not able to detect any CD154 protein other than that made by infected cells.
Nevertheless, we found that follicle center lymphoma B cells could be transduced with Ad-CD154, allowing for highlevel expression of murine CD154. Because murine CD154 is effective in ligating human CD40, 33 such cells were also induced to express important immune-costimulatory molecules, such as CD80 and CD54, that are upregulated following ligation of CD40. 7 Expression of such accessory molecules was associated with an enhanced capacity of Ad-CD154-infected cells to stimulate allogeneic or autologous blood T cells in mixed lymphocyte reactions. In contrast, follicle center lymphoma B cells transduced with adenovirus encoding the irrelevant protein, ␤-galactosidase, or Ad-hCD154 did not undergo such phenotypic changes and could not stimulate even normal allogeneic
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Figure 7
Allogeneic mixed lymphocyte reaction. 10 7 lymphoma cells were either non-infected (mock) or infected with Ad-CD154, AdhCD154, or Ad-LacZ at an MOI ratio of 300 for 2 days followed by mitomycin C treatment. T cells in the MLR. The failure of Ad-hCD154-infected lymphoma cells to upregulate expression of co-stimulatory molecules or to stimulate T cell responses is consistent with their inability to express hCD154 following infection with AdhCD154.
Despite the fact that Ad-CD154 infected lymphoma B cells had phenotypic changes similar to those of CD40-activated B cells, we did not observe any changes in lymphoma cell proliferation or survival following infection with Ad-CD154. This result contrasts with those of others that found either stimulation 34 or inhibition 35 of lymphoma cell growth following CD40 ligation. Such differences may be secondary to methods used to induce CD40 signaling. On the other hand, it could reflect heterogeneity among the different types of B cell lymphomas in their response to CD40 signaling. Consistent with this, prior studies by others on follicle center lymphoma also noted no change in growth or survival of the neoplastic B cells following CD40 ligation in the absence of exogenous cytokines, such as interleukin-4. 18, 19 As such, it appears that CD40 signaling does not independently stimulate the growth of follicle center lymphoma B cells.
The capacity of Ad-CD154-infected lymphoma cells to stimulate autologous T cells in MLR indicates that such cells may be useful for inducing autologous immune recognition of lymphoma cells. Interestingly, high proportions of nodal T cells were induced to express activation antigens, such as HLA-DR or CD71, following infection of the lymphoma cells with Ad-CD154 (Figure 8 ). In contrast, there were no detectable increases in expression of such activation antigens on the T cells of lymphoma cells infected with Ad-LacZ. This suggests that many of the T cells infiltrating the lymphoma tissue may have the capacity to react against lymphoma-associated antigens and/or adenovirus antigens provided that the lymphoma cells first are modified into proficient antigen presenting cells.
As such, infection of lymphoma cells ex vivo with Ad-CD154 could be used in a strategy similar to that used recently in patients with CLL.
14 Infusion of Ad-CD154 infected autologous CLL cells resulted in acute production of Th-1-type cytokines, such as interleukin-12 and interferon-gamma, increases in the absolute numbers of blood T cells, and reductions in numbers of circulating leukemia cells and lymph node sizes. Moreover, infusion of autologous Ad-CD154-infected CLL cells increased the numbers of T cells capable of recognizing both infected and non-infected leukemia cells in vitro. Conceivably, this strategy may also be used for patients with follicle center lymphoma, allowing for induction of a host anti-lymphoma immune response against putative lymphoma-associated antigens. Further studies are required to evaluate the safety and efficacy of this approach in follicle center B cell lymphoma, potentially allowing for a novel form of active immune gene therapy of patients with this disease.
